US Patent

US11931350 — Opioid receptor ligands and methods of using and making same

Method of Use · Assigned to Trevena Inc · Expires 2032-03-23 · 6y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of using opioid receptor ligands, such as Olinvyk, for treating pain and pain-related disorders.

USPTO Abstract

This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.

Drugs covered by this patent

Olinvyk (OLICERIDINE) · Trevena

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2986`	—	Olinvyk
`U-2986`	—	Olinvyk
`U-2986`	—	Olinvyk

Patent Metadata

Patent number: US11931350
Jurisdiction: US
Classification: Method of Use
Expires: 2032-03-23
Drug substance claim: Yes
Drug product claim: No
Assignee: Trevena Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.